Product
olverembatinib
1 clinical trial
2 indications
Indication
Chronic Myeloid LeukemiaIndication
Chronic PhaseClinical trial
This is a Global, Multi-center, Open-label Randomized and Registrational Phase 3 Study of Olverembatinib (HQP1351) in Patients With Chronic Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2025-12-01